2019
Personalizing Treatment Selection for Breast Cancer
Pusztai L, Yeoh C. Personalizing Treatment Selection for Breast Cancer. 2019, 297-324. DOI: 10.1201/9780429066504-14.Peer-Reviewed Original ResearchBreast cancerTreatment selectionClinical outcomesRisk of recurrenceMultiple treatment optionsParticular clinical outcomesCurrent treatment modalitiesCancer-related deathMore effective treatmentsProbability of benefitBreast cancer researchUnited States FoodSurgical resectionProbability of responseTrastuzumab therapyCommon malignancyTreatment optionsClinicopathologic variablesPatient preferencesSpecific therapyTreatment modalitiesMulti-gene testsDisease outcomeMolecular differencesEffective treatment
2010
Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research.
Saad E, Katz A, Pusztai L, Hoff P, Buyse M. Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research. Journal Of Clinical Oncology 2010, 28: 1084-1084. DOI: 10.1200/jco.2010.28.15_suppl.1084.Peer-Reviewed Original Research
2007
Gene-expression microarrays provide new prognostic and predictive tests for breast cancer
Gong Y, Symmans WF, Pusztai L. Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics 2007, 8: 1359-1368. PMID: 17979510, DOI: 10.2217/14622416.8.10.1359.Peer-Reviewed Original ResearchConceptsBreast cancerSystemic therapySpecific systemic therapySystemic therapy agentsGene expression microarraysBreast cancer researchProbability of responseTherapeutic regimensClinicopathologic variablesNecessary therapyDisease outcomeIndividual patientsAccurate markerClinical decisionIndividual tumorsCancerPredictive indicatorTherapyPredictive testIndividual basisPatientsCancer researchTherapy agentsMolecular differencesRecent progression